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j8-Adrenergic Receptor Blockade by Propranolol Enhances Retention in a
Multitrial Passive-Avoidance Procedure
Allen M. Schneider, Nancy S. Koven,
Kimberly A. Lombardo, and Dimitriy A. Levin
Swarthmore College
Peter E. Simson
Miami University
The effect of j3-adrenergic receptor blockade on retention in a mildly aversive passive-avoidance
procedure was investigated. Rats were given passive-avoidance training—1 trial per day for 4 days—and
were administered saline, the centrally and peripherally acting /3-adrenergic blocker propranolol (4 or 10
mg/kg ip), or the peripherally acting (3-adrenergic blocker sotalol (4 or 10 mg/kg ip) immediately or 2
hr after the 1st trial. Enhanced retention occurred only with the higher dose (10 mg/kg) of propranolol
and only when it was administered immediately after training. The enhanced retention produced by
propranolol is discussed in terms of opposing, regionally specific actions of 0-adrenergic receptor-
mediated neural circuits on modulation of memory.
It is well established that adrenergic systems in both the central
nervous system (CNS) and the peripheral nervous system (PNS)
modulate the strength of retention (Introini-Collison, Saghafi, No-
vak, & McGaugh, 1992; McGaugh, Liang, Bennett, & Sternberg,
1984). One site in the brain in which norepinephrine clearly plays
an important role in the modulation of retention is the amygdala
(Liang, McGaugh, & Yao, 1990; McGaugh, Introini-Collison,
Cahill, Kim, & Liang, 1992), where blockade of /3-adrenergic
receptors through local application of propranolol, with some
exception (Izquierdo et al., 1992), impairs retention (Gallagher,
Kapp, Musty, & Driscoll, 1977; Lennartz, Hellems, Mook, &
Gold, 1996). Less clear, however, is the effect on modulation of
antagonizing /3-adrenergic activity in the brain as a whole, the
PNS, or both. Indeed, although evidence from the literature on
humans is mixed regarding the ability of systemically administered
/3-adrenergic blockers to impair retention (Cahill, Prins, Weber, &
McGaugh, 1994; Dimsdale, Newton, & Joist, 1989; McAinsh &
Cruikshank, 1990; van Stegeren, Everaerd, Cahill, McGaugh, &
Gooren, 1998), in rats or mice systemic administration of the
centrally and peripherally acting /3-adrenergic blocker propranolol,
with some exception (Przybyslawski, Roullet, & Sara, 1999),
appears unable to impair retention in the passive-avoidance pro-
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cedure (Decker, Gill, & McGaugh, 1990; McGaugh, 1989; Saha,
Datta, & Sharma, 1991).
One explanation for the inability of systemically, as opposed to
locally, administered propranolol to impair retention in the
passive-avoidance procedure is that blockade of (3-adrenergic re-
ceptors at sites outside the sphere of influence of the locally
applied drug either directly (through receptor activity per se) or
indirectly (e.g., via /3-adrenergic receptor-mediated neural circuits)
opposes the impairment of retention produced by local application
of the /3-adrenergic blocker. That is, these findings raise the
intriguing possibility that, depending on the site of action of
/3-adrenergic blockade, impairment or enhancement of retention
may occur.
That blockade of /3-adrenergic receptors at different sites in the
brain may have opposing effects on modulation of retention is
suggested by in vitro electrophysiological studies showing that
stimulation of /3-adrenergic receptors in different parts of the
amygdala has opposing effects on short-term potentiation (STP).
Specifically, stimulation of /3-adrenergic receptors in the medial
amygdala enhances STP, whereas stimulation of (3-adrenergic
receptors in the lateral amygdala suppresses STP (Watanabe, Ike-
gaya, Saito, & Abe, 1996).
If the opposing action of /3-adrenergic receptors on STP in
different regions of the amygdala also occurs with the action of
/3-adrenergic receptors on modulation of retention, and if the mode
of drug administration affects /3-adrenergic receptors in different
regions of the amygdala to different degrees, one might expect
local and systemic administration of /3-adrenergic blockers to
affect retention differentially. Indeed, one might predict that block-
ade of /3-adrenergic receptors through systemic drug administra-
tion would enhance retention. The purpose of the present study
was to test the hypothesis that blockade of 3-adrenergic receptors
through systemic administration of propranolol enhances retention.
We tested this hypothesis by administering, immediately after
training of a mildly aversive passive-avoidance task, the periph-
erally and centrally acting (3-adrenergic antagonist propranolol (4
or 10 mg/kg ip) or the peripherally acting /3-adrenergic antagonist
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sotatol (4 or 10 mg/kg ip). The passive-avoidance task was other-
wise identical to the commonly used one-trial passive-avoidance
procedure (i.e., rats were given a mildly aversive footshock for
stepping from a lighted to a dark compartment), with one excep-
tion: Instead of a single training trial, a multitrial procedure con-
sisting of one trial per day for 4 days was used. Saline or drugs
were administered only after the first training trial, and the en-
hancing or impairing effect of the drugs on retention, relative to
saline controls, was measured in terms of their effect on step-
through latencies (STLs) during subsequent training trials.
A trial consisted of the following: Each rat was placed in the lighted
compartment facing away from the sliding door. After 15 s the door was
raised, the rat was allowed to step into the dark compartment, the door was
lowered, and shock (if this was one of the first three trials and if the rat was
not in the no-shock control groups) was delivered to the floor of the
compartment. The rat remained in the dark compartment for 15 s and was
then removed and administered drug or saline (if this was the first trial)
either immediately or 2 hr later. After each rat completed a trial, the
apparatus was cleaned.
STLs on Trials 2-4 served as the measure of retention. If STLs exceeded
180 s, the tria! was terminated and the rat was retired from the experiment.
Method
Experimental Design
Before training on Day 1, the rats were randomly assigned to one of five
groups- saline, propranolol 4 mg/kg, propranolol 10 mg/kg, sotalol 4
mg/kg, or sotalol 10 mg/kg—then were trained, and then immediately after
training were given their designated treatment. Because the higher dose (10
mg^cg) but not the lower dose (4 mg/kg) of propranolol was found to
increase STLs, two control experiments were conducted. In one experi-
ment, for the assessment of the time-dependent effects of the higher dosage
of propranolol, subjects received saline or propranolol (10 mg/kg) 2 hr after
the first training trial. In a second experiment, for the assessment of the
potentially aversive effect of the higher dosage of propranolol in and of
itself, subjects received saline or propranolol (10 mg/kg ip) immediately
after the first training trial in the absence of shock (no-shock control
groups).
Subjects
The subjects (« = 86) were male Long-Evans hooded rats (obtained
from Harlaa Sprague Dawley, Indianapolis, IN) weighing 250-325 g at the
start of the experiment. The rats were housed 2 to a cage with access to
food and water ad libitum. The colony room was maintained at 70 °F and
was illuminated on a 12-hr light-dark cycle (lights on at 9:00 a.m,)- Each
rat was handled daily for 15 s and was in the laboratory for at least 9 days,
but not more than 18 days, before the start of the experiment AH exper-
iments were conducted between 10:00 a.m. and 3:00 p.m.
Apparatus
The rats were trained in a standard trough-shaped passive-avoidance
apparatus that consisted of a small lighted compartment (20 X 28 X 18
cm), illuminated by a 95-W bulb, connected to a larger dark compartment
(20 x 28 x 42 cm). A manually operated sliding door separated the two
compartments. The top of each compartment was hinged, and the floor of
each compartment was made of stainless steel plates. A constant-current
Lafayette Master Shocker (Model 2400SS; Lafayette, IN), set to de-
liver 0.35 mA of 1-s duration, was connected to the floor of the large
compartment. The apparatus was located in a quiet, dimly illuminated
room.
Training and Testing Procedure
The rats received four training trials, one trial per day. On each trial, with
the exception of the last, all rats (except those in the no-shock control
groups, which did not receive shock on the first or last trial) received shock
for stepping from the lighted to the dark compartment STLs on the first
trial provided a measure of the subject's inherent (i.e., baseline) aversion of
the dark compartment. STLs on each of the next three trials provided a
measure of the subject's learned aversion of the dark compartment (i.e., a
measure of retention). Saline or drugs were administered immediately or 2
hr after the first—and only the first—trial.
Drug Administration and Drug Doses
The rats were injected intraperitoneally with saline, the peripherally and
centrally acting ^-adrenergic antagonist dl-propranolo! hydrochloride (4
or 10 mg/kg; Sigma Chemical, St. Louis, MO), or the peripherally acting
0-adrenergic antagonist sotalol hydrochloride (4 or 10 mg/kg; Berlex
Laboratories, Wayne, NJ). Drugs were dissolved in saline to a concentra-
tion of 4 or 10 mg/ml-
Statistics
Data were analyzed with one-way analyses of variance (ANOVAs) and
protected-? tests. Any p values (two-tailed) of less than .05 were taken as
statistically significant.
Results
The results indicate, first and foremost, that blockade of
(3-adrenergic receptors through systemic administration of pro-
pranolol (10 mg/kg) markedly enhanced retention in the passive-
avoidance procedure, an effect that was both dose and time
dependent.
That the enhanced retention produced by propranolol could not
be attributed to aversive effects of the /3-adrenergic blocker is
evidenced by results from the no-shock control rats: In the absence
of shock, the STLs (mean ± SEM) on Day 2 (the first retention
day) for no-shock control rats receiving 10 mg/kg propranolol
(0.64 ± 0.40 min; n = 6) did not differ significantly, r(10) = 0,97,
p = .35, from STLs for no-shock control rats receiving saline
(0.24 ± 0.11 min; n = 6). The results of rats receiving shock (i.e.,
trained rats), however, revealed a much different picture.
Figure 1 shows the effect of /3-adrenergic receptor blockade on
retention over Days 2—4 in trained rats. The figure shows that
propranolol significantly affected retention on Day 2: Trained
subjects receiving the higher dose but not the lower dose of
propranolol immediately after the first trial (Day 1) exhibited
significantly greater retention on Day 2 than saline control sub-
jects. This description of the data is confirmed by an ANOVA that
revealed a significant drug effect on Day 2, F(4, 53) = 2.88, p <
,05, and by multiple comparison tests that indicated that the higher
but not the lower dose of propranolol enhanced retention: Rats that
received the higher dose of propranolol (10 mg/kg) had signifi-
cantly longer STLs than saline controls on Day 2, protected
K53) = 3.33, p < .01; rats that received the lower dose of
propranolol (4 mg/kg), although they showed a tendency toward
longer STLs than saline controls on Day 2, did not, protected
K53) = 1.62, p > .05. The lack of difference in STLs between
saline controls and the lower dose of propranolol continued on
Day 3, F(4, 53) = 1.19,p > .05, and Day 4, F(4, 53) = 234,p>
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Figure J, Mean (+SEM) step-through latency on Days 2, 3, and 4 for rats that received the /3-adrenergic
antagonists propranolol or sotalol, or saline, immediately after the first trial (Day I). Rats receiving propranolol
at a. dose of 10 mg/kg (Pro 10; n = 13) had significantly longer STLs on Day 2 than saline controls (Saline; n =
14). Rats receiving propranolol at a dose of 4 mg/kg (Pro 4; n = 13) or sotalol at a dose of 4 mg/kg (Sot 4; n —
9) or 10 mg/kg (Sot 10; n~9) did not differ in STLs on Day 2 compared with saline controls. The attrition rate
that occurred when rats met the 180-s cutoff on a given trial is reflected in the day-by-day sample size for each
group as follows: Saline, Day 2 = 14, Day 3 = 14, Day 4 = 7; Pro 10, Day 2 = 13, Day 3 = 7, Day 4 = 5;
Pro 4, Day 2 = 13, Day 3 = 10, Day 4 = 8; Sot 10, Day 2 = 9, Day 3 = 8, Day 4 = 7; Sot 4, Day 2 = 9,
Day 3 = 8, Day 4 = 5 . *p < .01, compared with saline controls.
.05. That the higher but not the lower dose of propranolol en-
hanced retention indicates that the |3-adrenergiu antagonist facili-
tates retention in a dose-dependent manner.
Figure 1 also shows the effects of the selective peripheral
/3-adrenergic antagonist sotalol on retention. Unlike propranolol,
sotalol administered immediately after passive-avoidance training
did not enhance retention regardless of whether subjects received
the higher dose or the lower dose. This description of the data is
confirmed by multiple comparison tests that indicated that rats that
received the higher dose, protected r(53) = 0.90, p > .05, or the
lower dose, protected r(53) = 1.22, p > .05, of sotalol did not
show significantly longer STLs than saline controls on Day 2. The
lack of difference in STLs between saline controls and both doses
of sotalol continued on Day 3, F(4, 53) = 1.19, p > .05, and
Day 4, F(4, 53) = 2.34, p > .05. That the selective peripheral
/3-adrenergic antagonist sotalol failed to enhance retention indi-
cates that blockade of peripheral /3-adrenergic receptors, by itself,
is not sufficient to enhance retention.
In contrast to the enhancement of retention observed when
propranolol (10 mg/kg) was administered immediately after the
first trial, when it was administered 2 hr after the first trial, STLs
(mean ± SEM) on Day 2 for rats receiving 10 mg/kg propranolol
(1.29 ± 0.51 min; n = 8) did not differ significantly, f(14) = 0.26,
p = .40, from STLs for rats receiving saline (1.11 ± 0.47 min; n =
8), This finding indicates that enhancement of retention produced
by propranolol is indeed time dependent and, therefore, most likely
the result of blockade of /3-adrenergic receptors occurring during a
critical period shortly after training when the strength of retention
is regulated by adrenergic activity.
Discussion
The present results indicate that propranolol (10 mg/kg), admin-
istered systemically immediately after training, markedly enhances
retention in a mildly aversive passive-avoidance task. The en-
hancement produced by propranolol depends on dose (occurring at
a dose of 10 mg/kg but not 4 mg/kg), time of administration
(occurring with immediate, but not delayed, administration), and
action in the CNS (occurring with propranolol but not sotalol).
That these results stand in marked contrast to the impairment of
retention found in the passive-avoidance procedure when propran-
olol is administered dkectly into the amygdala immediately after
training (Gallagher et al., 1977) indicates that the mode of pro-
pranolol administration is a critical factor in determining whether
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the /3-adrenergic blocker enhances or impairs retention. One ex-
planation for these results is that when propranolol is administered
systemically, its sphere of influence—and thus its effect on
/j-adrenergic receptors—is different than when it is administered
directly into the amygdala. Thus, unlike locally administered ad-
renergic drugs that may have effects limited to particular regions
(e.g., the basolateral nucleus) within the amygdala (Ferry & Mc-
Gaugh, 1999; Ferry, Roozendaal, & McGaugh, 1999), systemi-
cally administered drugs can enhance retention through adrenergic
blockade of different regions to different degrees inside or outside
the amygdala, or both.
It is our contention that propranolol's effect on retention, re-
gardless of the mode of administration, is the result of blockade of
excitatory and inhibitory /3-adrenergic receptors, receptor-
mediated neural circuits, or both. By virtue of their differential
regional distribution in the brain, however, we contend that these
opposing excitatory and inhibitory /3-adrenergic receptors or cir-
cuits are differentially blocked by propranolol depending on the
mode of administration; the blockade that dominates in turn de-
termines the strength of retention despite the counter-influence of
the other. It follows, then, that when systemic administration of
propranolol facilitates retention, it does so because the facilitating
effect of blockade of one type of /3-adrenergic receptor or circuit
(a receptor or circuit that in the absence of propranolol inhibits
retention) outweighs the impairing effect of blockade of the op-
posing type of /3-adrenergic receptor or circuit (a receptor or
circuit that in the absence of propranolol facilitates retention). By
the same reasoning, local administration of propranolol impairs
retention (Gallagher et al., 1977) because the impairing effect of
blockade of one type of /3-adrenergic receptor or circuit (a receptor
or circuit that in the absence of propranolol facilitates retention)
outweighs the facilitating effect of blockade of the opposing type
of /3-adrenergic receptor or circuit (a receptor or circuit that in the
absence of propranolol inhibits retention).
In view of the relative importance given to the role of the
adrenergic system in memory modulation, it is perhaps surprising
that a /3-adrenergic receptor or circuit inhibiting retention was not
uncovered earlier. One reason—the one that distinguishes the
present study— may be methodology: the unique combination of
a training procedure that produces weak retention with a drug
procedure using systemic administration of a relatively high dose
of j3-adrenergic blocker. On the other hand, although the notion of
an adrenergic memory-modulation circuit whose function is to
inhibit retention is new, the notion of inhibitory memory-
modulation circuits, in general, is not. Like the /3-blocker propran-
olol, the opiate and gamma-aminobutyric acid (GABA) antago-
nists naloxone and bicuculline, respectively, have been shown to
enhance retention; thus, like the proposed p-adrenergic receptor or
circuit in the present study, endorphin-mediated and GABAergic
receptors or circuits have been postulated to inhibit retention
(Brioni & McGaugh, 1988; Castellano, Brioni, & McGaugh, 1991;
Gallagher, 1982; Izquierdo, 1979; Messing et al., 1979). More-
over, the fact that propranolol has at least some antiserotonergic
activity (Middlemiss, Blakeborough, & Leather, 1977) leaves open
the possibility that propranolol may enhance retention, at least in
part, through a serotonergic receptor or circuit.
In conclusion, the enhancement of retention found in the present
study with systemic administration of the (3-adrenergic antagonist
propranolol indicates that the role of the /3-adrenergic system in
modulation of retention is complex and multifaceted. The present
results suggest the existence of a modulatory circuit that is sup-
pressed by a relatively high dose of propranolol and that is inhib-
itory in nature. Precisely how this circuit is related to the known
inhibitory memory modulation system remains to be determined.
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